What is LOPJLB’s current signal on ALNY?

LOPJLB’s latest quantitative signal on Alnylam Pharmaceuticals, Inc. (ALNY) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is ALNY in?

Alnylam Pharmaceuticals, Inc. (ALNY) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Alnylam Pharmaceuticals, Inc. (ALNY) do?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepat…

Alnylam Pharmaceuticals, Inc. (ALNY)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$223.82-1.41%Close

SELLRECOVERY · day 3

Company news

fool.com · 5d ago

Alnylam vs. Ionis: Here's the Better Bad-News Buy

defenseworld.net · 5d ago

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical Comparison

businesswire.com · 15d ago

AMVUTTRA® (vutrisiran) ‘Play by Play' Initiative Highlights Former Athletes' Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

seekingalpha.com · 16d ago

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform

zacks.com · 16d ago

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

fool.com · 17d ago

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right.

defenseworld.net · 22d ago

Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey

defenseworld.net · 23d ago

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Analysts

zacks.com · 23d ago

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

defenseworld.net · 24d ago

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook

defenseworld.net · 24d ago

Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

marketbeat.com · 24d ago

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook

marketbeat.com · 25d ago

Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial

seekingalpha.com · 27d ago

Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control Transcript

fool.com · 30d ago

Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture

defenseworld.net · 35d ago

Arizona State Retirement System Boosts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

defenseworld.net · 36d ago

Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Market news & ticker search · RSS for ALNY

FAQ

What is LOPJLB’s current signal on ALNY?: LOPJLB’s latest quantitative signal on Alnylam Pharmaceuticals, Inc. (ALNY) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is ALNY in?: Alnylam Pharmaceuticals, Inc. (ALNY) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Alnylam Pharmaceuticals, Inc. (ALNY) do?: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepat…

Alnylam Pharmaceuticals, Inc. (ALNY)

Key stats

Industry peers

Prediction markets

Company news

FAQ